By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


MedPointe Pharmaceuticals (Formerly Carter-Wallace, Inc.) 

265 Davidson Avenue

Somerset  New Jersey  08873-4120  U.S.A.
Phone: 732-564-2200 Fax:



Company News
FDA Approves MedPointe Pharmaceuticals's SOMA(R) 9/17/2007 6:12:43 AM
Meda AB (SE:MEDAa): Strategic Acquisition of MedPointe Inc. Completed 8/22/2007 10:06:53 AM
MedPointe Pharmaceuticals Announces the Appointment of John J. Howarth to Vice President of Public Affairs and Investor Relations 5/31/2007 10:38:01 AM
MedPointe Pharmaceuticals Settles Litigation with Hi-Tech Pharmacal (HITK) and Successfully Enforces Patent Covering its Tussi-12(R) D Products 5/30/2007 11:18:00 AM
Hi-Tech Pharmacal (HITK) Settles Litigation with MedPointe Pharmaceuticals and JFC Technologies, Acquires Vosol(R) Product Line 5/29/2007 12:19:58 PM
MedPointe Pharmaceuticals Release: Steroid-Free Astelin(R) Nasal Spray (R) Demonstrated Seasonal Allergy Symptom Improvement Within 15 Minutes in Clinical Study 2/26/2007 12:09:13 PM
MedPointe Pharmaceuticals Sets Leadership Succession And Management Realignment Plans Into Motion; Paul Edick Promoted To CEO 4/13/2006 12:32:58 PM
Christopher Pawlowicz, Human Resources Executive, Joins MedPointe Pharmaceuticals 4/12/2006 12:45:21 PM
MedPointe Pharmaceuticals Release: ZOMIG(R) (zolmitriptan) Nasal Spray Demonstrates Rapid Onset Of Migraine Relief With Lasting Effects In Large U.S. Study10/19/2005 5:12:42 PM
MedPointe Pharmaceuticals Release: New Study Confirms Long-Term Safety And Tolerability Of ZOMIG(R) (Zolmitriptan) Nasal Spray For Treatment Of Migraine10/19/2005 5:12:32 PM